Clinical trials · San Francisco, CA
Focal Segmental Glomerulosclerosis clinical trials in San Francisco
We’re tracking 3 recruiting focal segmental glomerulosclerosis studies with a site in or near San Francisco — including Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near San Francisco
- NCT06500702RecruitingPhase 2
Study of three drugs for FSGS or minimal change disease
This study tests three experimental drugs (frexalimab, brivekimig, and rilzabrutinib) for people ages 16 to 75 with a type of kidney disease called primary FSGS or minimal change disease. The goal is to see if these drugs can reduce protein in your urine and help protect your kidneys.
San Francisco, CaliforniaAges 16–75 - NCT07220083RecruitingPhase 3
A study of BI 764198 for people with FSGS kidney disease
This trial tests if a new medicine called BI 764198 can help people with a kidney condition called FSGS. It looks at whether the drug can reduce protein in the urine and protect kidney function.
San Francisco, CaliforniaAges 12 years+ - NCT01209000Recruiting
Study for children with new kidney protein loss
This study is for children (and some newly diagnosed patients) who have nephrotic syndrome—kidneys leaking a lot of protein. It aims to better understand the kidney condition (sometimes using biopsy) and support future care decisions.
San Francisco, CaliforniaAges Up to 80 years
Hear when a new Focal Segmental Glomerulosclerosis trial opens near San Francisco, CA
We’ll email you when one opens near San Francisco, CA — at most once a week, no account needed, unsubscribe anytime.
Focal Segmental Glomerulosclerosis trials in other cities
Where these studies are running near San Francisco
Institutions with a site for the recruiting focal segmental glomerulosclerosis studies listed above.
- Investigational Site
- Kaiser Permanente-San Francisco
- Stanford University
- University of California, San Francisco
- West Coast Kidney Institute
What taking part in a focal segmental glomerulosclerosis study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting focal segmental glomerulosclerosis studies in California.
Common questions
- Are there focal segmental glomerulosclerosis clinical trials near San Francisco?
- Yes. We're currently tracking 3 recruiting focal segmental glomerulosclerosis studies with a site near San Francisco, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a focal segmental glomerulosclerosis study near San Francisco?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in San Francisco to take part?
- Not necessarily. These studies have a site near San Francisco, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a focal segmental glomerulosclerosis trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New focal segmental glomerulosclerosis studies open near San Francisco regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.